please subscribe to the channel press the bell icon
you'll be notified of the latest videos this is sage for calkine media
today we're covering a trending topic three asx listed psychedelic medicine stocks to watch
in an attempt to expand the medical fields capabilities healthcare players are doing
research to investigate the potential of psychedelic medicines the promising potential
of psychedelic medicine has attracted the interest of market participants who are keen on an emerging
investment opportunity the future of psychedelic medicine lies in providing the treatment for the
most difficult to treat psychiatric indications including post-traumatic stress disorder or ptsd
and treatment resistant depression also the ongoing covert 19 pandemic has further highlighted
its impact on mental health let us discuss these asx listed psychedelic medicine stocks
in detail in canex healthcare limited clinical stage pharmaceutical development firm in
canadex healthcare is developing unique medicinal cannabis products as well as psychedelic medicines
to treat a generalized anxiety disorder obstructive sleep apnea lung inflammation
rheumatoid arthritis as well as inflammatory bowel disease in canex healthcare is conducting
clinical trials of psychotherapy to treat gad in collaboration with monash university melbourne
on 10th august 2021 the company disclosed that it had completed human research ethics committee
submission for a trial that combines the administration of psilocybin with specialized
therapy to patients with gad creso pharma limited australian-based cannabis player cresso farmer
is engaged in providing the best of cannabis to enhance the lives of people as well as
animals the company brings pharmaceutical expertise to the cannabis space and on the
15th of march 2021 chris o'farmer disclosed its entry into the psychedelic medicine space
announcing the agreement to acquire hallucinex life sciences inc a canadian psychedelics player
hallucinex is focused on the research and development as well as commercialization of
novel psychedelic compounds for the treatment of ptsd depression and other mental illnesses
on 15 january 2021 chris o'farmer disclosed the completion of hallucinex acquisitions
the acquisition provides cresso with access to the evolving global psychedelic
medicine market and interestingly hallucinex is continuously making progress for the clinical
development of psilocybin to treat ptsd emorya limited clinical drug development
and care delivery player amarilla limited is engaged in developing therapies that target
significant unmet medical needs the therapies of ameria are focused on obtaining approval
with major global regulators on the 5th of august 2021 maria entered in an exclusive agreement
with the university of western australia or uwa to develop a drug pipeline of new
psychedelic treatments and the agreement can help emd in becoming a leader in the development
of psychedelic assisted therapies for major neurological conditions
interestingly amarillo disclosed that the company will also direct an international commercial
patent strategy to make sure relevant intellectual property is suitably protected the bottom line
healthcare players are now focusing on the emerging space of a psychedelic medicine
which offers significant opportunities for the treatment of mental health related indications
and furthermore the covert 19 pandemic has further highlighted that mental health challenges
and the possibility for alternative solutions such as psychedelic assisted therapy if you do
like this information please like share comment on the video below subscribe to the channel and
if you press the bell icon you'll be notified of the latest videos but for more information
and regular updates head to the website kalkinemedia.com this is stage for kalkine media